查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193317

色素沉着过度治疗市场：按类型、疗法、分销渠道分类：2021-2031 年全球机会分析和行业预测

Pigmentation Disorder Treatment Market By Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 275 Pages | 商品交期: 2-3个工作天内

价格

全球色素障碍治疗市场预计将在 2021 年达到 7.9979 亿美元，到 2031 年达到 12.2091 亿美元，2022 年至 2031 年的复合年增长率为 4.3%。 .

色素异常症是一种皮肤组织异常，可以在初级保健实践中进行诊断、评估和治疗。 肤色是由黑色素引起的。 它由黑色素细胞（一种皮肤细胞）产生。 皮肤色素沉着障碍可由多种医学状况引起。 尤其是黄褐斑、皮肤黑化、白斑等，都是会导致皮肤变色的疾病。 白斑、白糠疹、花斑癣和炎症后色素沉着过度都是色素沉着过度的情况。

推动色素障碍治疗市场增长的主要因素之一是色素障碍患病率的增加。 例如，根据 2022 年 1 月出版的 IP 印度临床和实验皮肤病学杂誌，印度的白斑病患病率最高，约为 8.8%。 此外，不断增加的医疗保健支出、不断增加的临床研究和产品批准数量正在促进全球市场的增长。 例如，2022 年 7 月，因塞特公司获得美国食品和药物管理局 (FDA) 批准 1.5% 的 Opzelura (ruxolitinib) 乳膏用于局部治疗 12 岁及以上成人和儿童患者的非节段性白斑病。底部。

此外，对色素沉着保健的更多关注以及对健康问题的认识不断提高预计将推动市场增长。 然而，与治疗相关的高成本预计会阻碍市场增长。 相反，不断上涨的医疗保健成本是预计在预测期内为市场增长创造有利可图机会的另一个因素。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析
  • 专利情况

第 4 章色素异常治疗市场：按类型

  • 概览
    • 市场规模和预测
  • 白癜风
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
    • 白斑色素沉着药市场：按类型分类
      • 市场规模和按细分市场预测：按地区
      • 非细分市场规模趋势和预测：按地区
  • 黄褐斑
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章色素异常治疗市场：按治疗分类

  • 概览
    • 市场规模和预测
  • 肾上腺皮质激素
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 钙调磷酸□抑製剂
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章色素沉着治疗市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 药店和零售药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 在线药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章色素异常治疗市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机遇
    • 北美市场规模和预测：按类型
      • 北美白斑色素沉着治疗市场：按类型分类
    • 北美市场规模和预测：按处理方法
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机遇
    • 欧洲市场规模和预测：按类型
      • 欧洲白斑色素沉着治疗市场：按类型分类
    • 欧洲市场规模和预测：按处理方法
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机遇
    • 亚太市场规模和预测：按类型
      • 亚太地区白斑色素沉着治疗市场：按类型分类
    • 亚太地区市场规模和按处理方法预测
    • 亚太市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机遇
    • LAMEA 市场规模和预测：按类型
      • LAMEA 白斑色素沉着治疗市场：按类型分类
    • LAMEA 市场规模和预测：按处理方法
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • Arcutis Biotherapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc
  • Incyte Corporation
  • Dermavant Science Inc.
  • Viatirs Inc.（Mylan N.V.）
  • Galderma SA
  • Obagi Cosmeceuticals LLC
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Ltd
Product Code: A11229

The global pigmentation disorder treatment market was valued at $799.79 million in 2021, and is estimated to reach $1,220.91 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.

Pigmentation disorder is abnormality in the skin tissues, which can be diagnosed, evaluated, and treated in primary care practices. Skin color is caused by the melanin pigment. Melanocytes, a type of skin cell, produces it. Disorders of skin pigmentation can be brought on by a variety of medical conditions. Melasma, dark skin, and vitiligo are a few particular disorders that can result in skin discoloration. Vitiligo, pityriasis alba, tinea versicolor, and post inflammatory hypopigmentation are all conditions of hypopigmentation.

One of the major factors that drives the growth of the pigmentation disorder treatment market is increase in prevalence of pigmentation disorders. For instance, according to IP Indian Journal of Clinical and Experimental Dermatology published in January 2022, India is considered to have highest prevalence of vitiligo about 8.8%. In addition, increase in healthcare spending, rise in number of clinical research and product approvals contribute toward the global market growth. For instance, in July 2022 Incyte Corporation got approval from U.S. Food and Drug Administration (FDA) for its Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Furthermore, increase in the effort for pigmentation healthcare and rise in awareness about health problems are expected to drive the market growth. However high cost associated with the treatment is expected to hinder the market growth. Conversely, increase in healthcare expenditure is another factor expected to create lucrative opportunities for market growth during the forecast period

The pigmentation disorder treatment market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is categorized into vitiligo, melasma and others. The vitiligo segment is further classified as segmental and non-segmental. By treatment, it is divided into corticosteroids, calcineurin Inhibitor, and others. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Arcutis Biotherapeutics, Inc, Astellas Pharma Inc., Bausch Health Companies Inc, Dermavant Sciences Inc, Dr. Reddy,s Laboratories Ltd, Galderma S.A, Glenmark Pharmaceuticals Limited, Incyte Corporation, Obagi Cosmeceuticals LLC and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pigmentation disorder treatment market analysis from 2021 to 2031 to identify the prevailing pigmentation disorder treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pigmentation disorder treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pigmentation disorder treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Vitiligo
    • Type
    • Segmental
    • Non-segmental
  • Melasma
  • Others

By Treatment

  • Corticosteroids
  • Calcineurin inhibitor
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Arcutis Biotherapeutics
    • Astellas Pharma Inc.
    • Bausch Health Companies Inc
    • Incyte Corporation
    • Dermavant Science Inc.
    • Viatirs Inc. (Mylan N.V.)
    • Galderma SA
    • Obagi Cosmeceuticals LLC
    • Dr. Reddy's Laboratories Limited
    • Glenmark Pharmaceuticals Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Vitiligo
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Vitiligo Pigmentation Disorder Treatment Market by Type
      • 4.2.4.1 Segmental Market size and forecast, by region
      • 4.2.4.2 Non-segmental Market size and forecast, by region
  • 4.3 Melasma
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Corticosteroids
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Calcineurin inhibitor
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug store and retail pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PIGMENTATION DISORDER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
      • 7.2.2.1 North America Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.2.3 North America Market size and forecast, by Treatment
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Treatment
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Treatment
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Treatment
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
      • 7.3.2.1 Europe Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.3.3 Europe Market size and forecast, by Treatment
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Treatment
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Treatment
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Treatment
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Treatment
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Treatment
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Treatment
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
      • 7.4.2.1 Asia-Pacific Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Treatment
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Treatment
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Treatment
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Treatment
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Treatment
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Treatment
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
      • 7.5.2.1 LAMEA Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Treatment
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Treatment
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Treatment
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Treatment
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Arcutis Biotherapeutics
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Astellas Pharma Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Incyte Corporation
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Dermavant Science Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Viatirs Inc. (Mylan N.V.)
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Galderma SA
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Obagi Cosmeceuticals LLC
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Dr. Reddy's Laboratories Limited
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Glenmark Pharmaceuticals Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. PIGMENTATION DISORDER TREATMENT MARKET, FOR VITILIGO, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. PIGMENTATION DISORDER TREATMENT MARKET FOR VITILIGO, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 5. PIGMENTATION DISORDER TREATMENT MARKET, FOR SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. PIGMENTATION DISORDER TREATMENT MARKET, FOR NON-SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. PIGMENTATION DISORDER TREATMENT MARKET, FOR MELASMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. PIGMENTATION DISORDER TREATMENT MARKET FOR MELASMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. PIGMENTATION DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. PIGMENTATION DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 12. PIGMENTATION DISORDER TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. PIGMENTATION DISORDER TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. PIGMENTATION DISORDER TREATMENT MARKET, FOR CALCINEURIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. PIGMENTATION DISORDER TREATMENT MARKET FOR CALCINEURIN INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. PIGMENTATION DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. PIGMENTATION DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 19. PIGMENTATION DISORDER TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. PIGMENTATION DISORDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. PIGMENTATION DISORDER TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. PIGMENTATION DISORDER TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. PIGMENTATION DISORDER TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. PIGMENTATION DISORDER TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 25. PIGMENTATION DISORDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 33. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 36. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. UK PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 52. UK PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 53. UK PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 56. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 71. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 73. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 74. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 75. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 76. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 103.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 104.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
  • TABLE 105.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 106.ARCUTIS BIOTHERAPEUTICS: NET SALES,
  • TABLE 107.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
  • TABLE 108.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 109.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
  • TABLE 110.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 111.ASTELLAS PHARMA INC.: NET SALES,
  • TABLE 112.ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 113.BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
  • TABLE 114.BAUSCH HEALTH COMPANIES INC: OPERATING SEGMENTS
  • TABLE 115.BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
  • TABLE 116.BAUSCH HEALTH COMPANIES INC: NET SALES,
  • TABLE 117.BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
  • TABLE 118.INCYTE CORPORATION: COMPANY SNAPSHOT
  • TABLE 119.INCYTE CORPORATION: OPERATING SEGMENTS
  • TABLE 120.INCYTE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 121.INCYTE CORPORATION: NET SALES,
  • TABLE 122.INCYTE CORPORATION: KEY STRATERGIES
  • TABLE 123.DERMAVANT SCIENCE INC.: COMPANY SNAPSHOT
  • TABLE 124.DERMAVANT SCIENCE INC.: OPERATING SEGMENTS
  • TABLE 125.DERMAVANT SCIENCE INC.: PRODUCT PORTFOLIO
  • TABLE 126.DERMAVANT SCIENCE INC.: NET SALES,
  • TABLE 127.DERMAVANT SCIENCE INC.: KEY STRATERGIES
  • TABLE 128.VIATIRS INC. (MYLAN N.V.): COMPANY SNAPSHOT
  • TABLE 129.VIATIRS INC. (MYLAN N.V.): OPERATING SEGMENTS
  • TABLE 130.VIATIRS INC. (MYLAN N.V.): PRODUCT PORTFOLIO
  • TABLE 131.VIATIRS INC. (MYLAN N.V.): NET SALES,
  • TABLE 132.VIATIRS INC. (MYLAN N.V.): KEY STRATERGIES
  • TABLE 133.GALDERMA SA: COMPANY SNAPSHOT
  • TABLE 134.GALDERMA SA: OPERATING SEGMENTS
  • TABLE 135.GALDERMA SA: PRODUCT PORTFOLIO
  • TABLE 136.GALDERMA SA: NET SALES,
  • TABLE 137.GALDERMA SA: KEY STRATERGIES
  • TABLE 138.OBAGI COSMECEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 139.OBAGI COSMECEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 140.OBAGI COSMECEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 141.OBAGI COSMECEUTICALS LLC: NET SALES,
  • TABLE 142.OBAGI COSMECEUTICALS LLC: KEY STRATERGIES
  • TABLE 143.DR. REDDY'S LABORATORIES LIMITED: COMPANY SNAPSHOT
  • TABLE 144.DR. REDDY'S LABORATORIES LIMITED: OPERATING SEGMENTS
  • TABLE 145.DR. REDDY'S LABORATORIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 146.DR. REDDY'S LABORATORIES LIMITED: NET SALES,
  • TABLE 147.DR. REDDY'S LABORATORIES LIMITED: KEY STRATERGIES
  • TABLE 148.GLENMARK PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 149.GLENMARK PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 150.GLENMARK PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 151.GLENMARK PHARMACEUTICALS LTD: NET SALES,
  • TABLE 152.GLENMARK PHARMACEUTICALS LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.PIGMENTATION DISORDER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.PIGMENTATION DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 3.PIGMENTATION DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.PIGMENTATION DISORDER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.PIGMENTATION DISORDER TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF VITILIGO PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MELASMA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.PIGMENTATION DISORDER TREATMENT MARKET,BY TREATMENT,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CALCINEURIN INHIBITOR PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.PIGMENTATION DISORDER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 26.PIGMENTATION DISORDER TREATMENT MARKET BY REGION,2021
  • FIGURE 27.U.S. PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.UK PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.ARCUTIS BIOTHERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 53.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)
  • FIGURE 54.BAUSCH HEALTH COMPANIES INC.: NET SALES ,($MILLION)
  • FIGURE 55.INCYTE CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 56.DERMAVANT SCIENCE INC..: NET SALES ,($MILLION)
  • FIGURE 57.VIATIRS INC. (MYLAN N.V.).: NET SALES ,($MILLION)
  • FIGURE 58.GALDERMA SA.: NET SALES ,($MILLION)
  • FIGURE 59.OBAGI COSMECEUTICALS LLC.: NET SALES ,($MILLION)
  • FIGURE 60.DR. REDDY'S LABORATORIES LIMITED.: NET SALES ,($MILLION)
  • FIGURE 61.GLENMARK PHARMACEUTICALS LTD.: NET SALES ,($MILLION)